Expansion follows successful multi-year pilots in Massachusetts and California, and longstanding Pod takeback programs in Europe, Canada, and Australia Insulet Corporation (NASDAQ: PODD) (“Insulet” or ...

ACTON, Mass., December 15, 2025--(BUSINESS WIRE)--Insulet Corporation (NASDAQ: PODD) ("Insulet" or the "Company"), the global leader in tubeless insulin pump technology with its Omnipod brand of ...

Insulet Corporation PODD recently received FDA 510(k) clearance for significant enhancements to the Omnipod 5 Automated Insulin Delivery System. These updates to the Omnipod 5 algorithm set a new ...

Please provide your email address to receive an email when new articles are posted on . You've successfully added to your alerts. You will receive an email when new content is published. Click Here to ...

Pease announced, "For the fourth quarter, we expect total Omnipod revenue growth of 27% to 30% and total company growth of 25% to 28%." She guided for fourth quarter U.S. Omnipod growth of 24% to 27% ...

Medical devices are not particularly known for bold branding. Omnipod, an insulin pump owned by Insulet, aims to change that with its own custom color created with Pantone. Last week, the 25-year-old ...

Insulet is bringing a splash of color to the diabetes technology market. Working with Pantone, the insulin pump company has created the “bright and joyful tropical orange yellow” color Omnipod Mango.

Insulet Corporation (NASDAQ:PODD) reported second-quarter adjusted earnings of $1.17 per share, beating the consensus of 92 cents. PODD shares are rallying today. Track live prices here. The automated ...

Insulet’s Q4 revenue hit $597.5 million, up 17.2%, beating the $582.81 million consensus. Omnipod revenue climbed 16.9% to $585.7 million, with international sales up 33.5%. See the seasonal trading ...

Antonia Haynes is a Game Rant writer who resides in a small seaside town in England where she has lived her whole life. Beginning her video game writing career in 2014, and having an avid love of ...

The expanded approval for the Omnipod 5 system now allows automated insulin delivery (AID) for adults with type 2 diabetes, offering a new option for better glucose management without daily injections ...